SunTrust analyst Gregg Gilbert lowered his price target on Perrigo to $46 and kept his Hold rating, saying his analysis suggests that the earnings dilution from the sale or spin of its Rx Pharma business would be “significant” at over 20%. The analyst adds that his new price target is based on the company’s “more conservative growth assumptions” as he looks ahead to more specifics on the separation of its Rx business at the May 9th Investor Day.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.